Indication
Sublesional Bone Loss Secondary to SCI
1 clinical trial
2 products
1 drug
Clinical trial
Romosozumab to Improve Bone Mineral Density and Architecture in Chronic SCIStatus: Active (not recruiting), Estimated PCD: 2026-02-05
Product
RomosozumabProduct
DenosumabDrug
Varlilumab